Biobanking study for sarcopenia in Austria
Sarcopenia in Cirrhosis and Chronic Inflammatory Bowel Disease: An Austrian Biobanking Study
This study is trying to collect health information and samples from people with liver cirrhosis and chronic inflammatory bowel disease in Austria to better understand and research sarcopenia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Graz Academic / other |
| Locations | 1 site (Graz) |
| Trial ID | NCT06632743 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a biobanking initiative in Graz, Austria, focusing on sarcopenia in patients with liver cirrhosis and chronic inflammatory bowel disease. It will collect a standardized dataset that includes routine clinical and biochemical tests, biosamples for novel biomarker assessment, and advanced clinical evaluations. The goal is to enhance research on sarcopenia by extending the registry to all tertiary liver care centers across Austria. This initiative addresses the high prevalence and diagnostic challenges of sarcopenia in aging and chronic disease populations.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with liver cirrhosis or chronic inflammatory bowel disease who can provide informed consent.
Not a fit: Patients with severe cognitive disorders or advanced hepatocellular carcinoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and diagnosis of sarcopenia, ultimately enhancing patient care and outcomes.
How similar studies have performed: While there is ongoing research into sarcopenia, this biobanking approach is relatively novel and aims to fill significant gaps in understanding the condition.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18y * Informed consent * CT/MRI scan as part of routine care within +/-2 month of the study visit Exclusion Criteria: * Hepatic encephalopathy \> grade 2 and or other cognitive disorder not allowing informed consent * Hepatocellular carcinoma stage BCLC C or D * Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol
Where this trial is running
Graz
- Medical University of Graz — Graz, Austria (Recruiting)
Study contacts
- Study coordinator: Vanessa Stadlbauer, MD
- Email: vanessa.stadlbauer@medunigraz.at
- Phone: +43 316 385 82282
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.